{"name":"Viracta Therapeutics","slug":"viracta","ticker":"VIRX","exchange":"NASDAQ","domain":"viracta.com","description":"Viracta Therapeutics is a clinical-stage oncology biotechnology company focused on developing novel therapies targeting cancer cells. The company's lead product, vosaroxin, is being investigated for the treatment of acute myeloid leukemia (AML). Viracta Therapeutics has a strong pipeline of candidates in various stages of development, with a focus on addressing unmet medical needs in oncology.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Ivor Royston","sector":"Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":669000,"revenueGrowth":0,"grossMargin":0,"rdSpend":12259000,"netIncome":-51058000,"cash":56692000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Vosaroxin patent cliff ($0.0B at risk)","drug":"Vosaroxin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Viracta Therapeutics Announces FDA Clearance of IND for VT-846","summary":"Viracta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VT-846, a novel, small molecule inhibitor of the transcription factor, E2F1.","drugName":"VT-846","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Viracta Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Viracta Therapeutics reported its financial results for the third quarter of 2022, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"trial","headline":"Viracta Therapeutics Announces Positive Interim Data from Phase 1/2 Clinical Trial of VT-846","summary":"Viracta Therapeutics announced positive interim data from the Phase 1/2 clinical trial of VT-846 in patients with relapsed or refractory AML.","drugName":"VT-846","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNLU0wR3U1aFlZcnVCcDdYNUtoSWNXcnRScHJEVUgyeG5Tb3F6WnpsS3Q2NU5ZOHdoXzBhb0loa1NEN3AxQ0M1UXFaOER6WUdhdE44UVRFNVJNMlItYnZ3MEVteG9ia3BxQnN4eDhZTnY1MmVqTUU1Zno1di1vakg0bkFTY21ycUJaVXVEWkZxM2M4QWNiSm1XSnJYcXp0ejdOczZHZ3hnNmVGU2JKdWllZmNuWmZyX3VURUd3?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"VIRX (Viracta Therapeutics) PB Ratio : (As of Apr. 04, 2026) - GuruFocus","headline":"VIRX (Viracta Therapeutics) PB Ratio : (As of Apr. 04, 2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LUkFvZkFXQWhoUHQ1ZW1tTFlfRGEtaXlYTlhIVl83NXJjV1l3LWZoelV1OHE1Nk1paUVOdndWUWxaVzFnOTNiRGZQdjIxM2ticU1n?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"VIRX Stock Price, News & Analysis - Stock Titan","headline":"VIRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOMXVQZDgtME52NnNONkZxQTZWcmxBSm03Y1JwX1hOQ0VUUm04bEtoLTJaamVYUlBLSnBJWFBFSHV2NUlLOTEwRF9aakxRTHpXRTBmQzRiT0lQaTlzdTduNkF1cEF3RHlfSUZxX2s1aFY4cTBYUGpjSF84YnYwSnNOZ3lBVmVPRDV0Q0xxTGNJNkw5cDMzYS1wd2laMFM1Y3dHOVh2aE9yX3c0bW5mSV9SQXhaU3l6MW0ySDhB?oc=5","date":"2025-02-05","type":"pipeline","source":"Investing.com","summary":"Viracta Therapeutics to cease operations and seek alternatives - Investing.com","headline":"Viracta Therapeutics to cease operations and seek alternatives","sentiment":"neutral"},{"date":"2025-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNdm85blpMWDQtX01yTGR6SFgwellIZk5Jb2tCSU5nck9EZEtXa3VyN2ZlNjNNQlpOSVNPTlZzR0ZRMWY1OTl1ZXBaeHVrMWdHZVFycF9XOF80eW1henFvQk9vaWhaaHFRZ2ZHekctTTJxZ2RKcTFiSWlfLWdlQmhXQW9fS2RjWFhzeFJhWU1oeU9PY0Y3d3lWd00zY0U2bmF0eVM4N1VR?oc=5","date":"2025-02-03","type":"pipeline","source":"Investing.com","summary":"Viracta Therapeutics to be delisted from Nasdaq - Investing.com","headline":"Viracta Therapeutics to be delisted from Nasdaq","sentiment":"neutral"},{"date":"2025-01-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-01-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-01-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUmhCcEQzMHlPbG5CSFlQMGpNc2dMaHBON3hhMU9TUE92V05ZYktoQkNVUWhwVDN5U1l1TGcxaXdtZXJfVFo0TGxtSC1QakNoUDdCYmdiVVBUWlk0ZXFSb2I5eEFsbzJQY1gwb1U1RW9QVmJZUVozakdnaFFNcXl6dmVLTjFkVk0wQl9kNk1kRm5BUmF3M21JVw?oc=5","date":"2024-12-27","type":"pipeline","source":"Yahoo Finance","summary":"Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance","headline":"Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure","sentiment":"neutral"},{"date":"2024-12-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Vosaroxin","drugSlug":"vosaroxin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Celgene","Gilead Sciences"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":669000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":669000,"period":"2017-12-31"},{"value":669000,"period":"2017-03-31"},{"value":2536000,"period":"2016-12-31"},{"value":2536000,"period":"2016-12-31"},{"value":676000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12259000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51058000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":56692000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}